X-linked tumor suppressors: Perplexing inheritance, a unique therapeutic opportunity

Trends in Genetics

Volumn 26, Issue 6, 2010, Pages 260-265

  Liu, Yang ^a   Wang, Lizhong ^a   Zheng, Pan ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR WTX; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; AUTOSOMAL INHERITANCE; BREAST CANCER; CANCER CELL; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME INACTIVATION; DOMINANT INHERITANCE; GENE ACTIVATION; GENE DOSAGE; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; INHERITANCE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RECESSIVE INHERITANCE; X CHROMOSOME LINKAGE;

ANIMALS; GENES, X-LINKED; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 77953288029     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2010.03.004     Document Type: Article

References (50)

1. Lyon M.F. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961, 190:372-373.
2. Lin H., et al. Dosage compensation in the mouse balances up-regulation and silencing of X-linked genes. PLoS biology 2007, 5(12):e326.
3. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U. S. A. 1971, 68(4):820-823.
4. Woolf C.M. An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960, 13:739-744.
5. Monroe K.R., et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat. Med. 1995, 1(8):827-829.
6. Narod S.A., et al. The impact of family history on early detection of prostate cancer. Nat. Med. 1995, 1(2):99-101.
7. Plna K., Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J. Urol. 2001, 166(6):2129-2133.
8. Forman D., et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br. J. Cancer 1992, 65(2):255-262.
9. Heimdal K., et al. Familial testicular cancer in Norway and southern Sweden. Br. J. Cancer 1996, 73(7):964-969.
10. Xu J., et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. 1998, 20(2):175-179.
11. Brown W.M., et al. Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci. Br. J. Cancer 2004, 90(2):510-514.
12. Lange E.M., et al. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin. Cancer Res. 1999, 5(12):4013-4020.
13. Bochum S., et al. Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. The Prostate 2002, 52(1):12-19.
14. Schleutker J., et al. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin. Cancer Res. 2000, 6(12):4810-4815.
15. Baffoe-Bonnie A.B., et al. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Hum. Genet. 2005, 117(4):307-316.
16. Yaspan B.L., et al. A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer. Hum. Genet. 2008, 123(4):379-386.
17. Eeles R.A., et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 2008, 40(3):316-321.
18. Gudmundsson J., et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 2008, 40(3):281-283.
19. Rapley E.A., et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat. Genet. 2000, 24(2):197-200.
20. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10(10):704-714.
21. Spatz A., et al. X-chromosome genetics and human cancer. Nat Rev Cancer 2004, 4(8):617-629.
22. Bennett C.L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27(1):20-21.
23. Brunkow M.E., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, 27(1):68-73.
24. Chatila T.A., et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 2000, 106(12):R75-81.
25. Wildin R.S., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 2001, 27(1):18-20.
26. Tommasini A., et al. X-chromosome inactivation analysis in a female carrier of FOXP3 mutation. Clin. Exp. Immunol. 2002, 130(1):127-130.
27. Zuo T., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129(7):1275-1286.
28. Wang L., et al. Somatic single hits inactivate the X-Linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009, 16(4):336-346.
29. Merlo A., et al. FOXP3 expression and overall survival in breast cancer. J. Clin. Oncol. 2009, 27(11):1746-1752.
30. Zuo T., et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 2007, 117(12):3765-3773.
31. Liu R., et al. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Research 2009, 69(6):2252-2259.
32. Rivera M.N., et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007, 315(5812):642-645.
33. Major M.B., et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007, 316(5827):1043-1046.
34. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nature reviews 2008, 8(5):387-398.
35. Perotti D., et al. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 2008, 27(33):4625-4632.
36. Wegert J., et al. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes. Chromosomes Cancer 2009, 48(12):1102-1111.
37. Jenkins Z.A., et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat. Genet. 2009, 41(1):95-100.
38. Meetei A.R., et al. X-linked inheritance of Fanconi anemia complementation group B. Nat. Genet. 2004, 36(11):1219-1224.
39. Brandau O., et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum. Mol. Genet. 1999, 8(13):2407-2413.
40. Egeler R.M., et al. Documentation of Burkitt lymphoma with t(8;14) (q24;q32) in X-linked lymphoproliferative disease. Cancer 1992, 70(3):683-687.
41. Sumegi J., et al. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000, 96(9):3118-3125.
42. Pilia G., et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat. Genet. 1996, 12(3):241-247.
43. Hughes-Benzie R.M., et al. Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am. J. Med. Genet. 1992, 43(1-2):428-435.
44. Liu Y., et al. Activating transcription factor 2 and c-Jun-mediated induction of FoxP3 for experimental therapy of mammary tumor in the mouse. Cancer Research 2009, 69(14):5954-5960.
45. Marahrens Y., et al. Xist-deficient mice are defective in dosage compensation but not spermatogenesis. Genes Dev. 1997, 11(2):156-166.
46. Carrel L., Willard H.F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 2005, 434(7031):400-404.
47. Richardson A.L., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006, 9(2):121-132.
48. Perry M. Evaluation of breast tumour sex chromatin (Barr body) as an index of survival and response to pituitary ablation. Br. J. Surg. 1972, 59(9):731-734.
49. Ventura A., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445(7128):661-665.
50. Zhang H.Y., Sun H. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 2010, 287(1):91-97.